The U.S. Food and Drug Administration has granted orphan drug designation to AM152, the lead drug candidate under development at San Diego’s Amira Pharmaceuticals for treating idiopathic pulmonary fibrosis, a lung disease that makes it difficult to breathe. In a statement yesterday, the company says the designation provides a seven-year period of market exclusivity and potential tax credits and regulatory advantages to the developer of a new drug therapy for diseases that affect fewer than 200,000 people in the United States. Amira says it is completing early stage tests of a compound that seems to help block the activation of a cellular receptor implicated in tissue fibrosis and related disease processes.
By posting a comment, you agree to our terms and conditions.
Xconomy Insight · Special Report
Insights, wisdom, and inspiration on what it takes
From Our Editors · Special Report
Key indicators & expert insight from industry leaders
Xconomy
From Our Partners · Special Report
Advice for funding and future transformational opportunities
I just read the article & hope you hurry & make it available……..I would really like a treatment that works!
Good luck.